Exo1 NEW

Price	$38	$78	$139
Package	10mg	25mg	50mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-18

Product Details

Product Name: Exo1	CAS No.: 75541-83-2
Purity: 99.56%	Supply Ability: 10g
Release date: 2024/11/18

Product Introduction

Bioactivity

名稱	Exo1
描述	Exo1 is an inhibitor of the exocytic pathway
體外活性	Exo1 functions as a modifier of Golgi ARF1 GTPase activity, offering a unique approach to modulate Golgi function. Unlike agents like BFA, Exo1 targets a specific subset of membrane processes associated with the Golgi, presumably interacting with a different protein target, which could lead to distinct side effects. It disrupts vesicular traffic between the Endoplasmic Reticulum (ER) and the Golgi apparatus by altering Golgi structures, effectively inhibiting exocytosis with an IC50 value of approximately 20 μM. Furthermore, Exo1 impedes the acquisition of endoglycosidase H resistance in newly synthesized proteins, including VSVGts-GFP, transferrin, and MHC class I[1], indicative of its role in the intricate regulation of protein trafficking and modification.
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 22.5 mg/mL (82.34 mM)
關(guān)鍵字	Exo1 \| inhibit \| Exo-1 \| Exo 1 \| Inhibitor
相關(guān)庫	NO PAINS 化合物庫

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.